REMIMAZOLAM BESYLATE
| Brand name | BYFAVO |
|---|---|
| Active ingredient | REMIMAZOLAM BESYLATE |
| Strength | EQ 20MG BASE/VIAL |
| Dosage form | POWDER |
| Route | INTRAVENOUS |
| Modality | Small molecule |
| FDA approval | October 2020 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 9827251 | January 2034 | use U-2968 |
| 9561236 | April 2033 | use U-2968 |
| 10052334 | November 2031 | use U-2968 |
| 10195210 | November 2031 | use U-2968 |
| 10342800 | November 2031 | use U-2968 |
| 9737547 | November 2031 | use U-2968 |
| 10722522 | November 2031 | use U-2968 |
| 9914738 | July 2027 | product |
| 10472365 | July 2027 | use U-2968 |
| 9777007 | July 2027 | product |
| 10961250 | July 2027 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.